



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,

10.08.2022

Corporate Services Department,
BSE Ltd.,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai- 400001

Dear Sir,

Sub: Outcome Of Board Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Wednesday, 10th August, 2022, at 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034**, have inter-alia-

1. Approved the Standalone and Consolidated Unaudited Financial Results and Limited Review Report for the quarter ended 30th June, 2022.
2. Appointment of Mr. Pankaj Kumar Gupta (M. No: FCS6371), Practicing Company Secretary as Scrutinizer of the Company to conduct and scrutinize the entire process of voting at the 30th Annual General Meeting of the Company

In terms of the Provisions of Regulation 33 and of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

1. Unaudited Financial Results for the quarter ended 30th June, 2022.
2. Limited Review Report for the quarter ended 30th June, 2022.

The meeting of Board of Directors commenced at **05:00 P.M.** and concluded at **05:30 P.M.**

The above information will be available on the website of the company i.e <https://titanbiotechltd.com>

This is for your kind information and record please.

Thanking you,
Yours faithfully,
For Titan Biotech Limited


Charanjit Singh
Company Secretary
Membership Number: A12726



Limited Review Report on Unaudited standalone financial results of Titan Biotech Limited for the quarter ended 30th June 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015

To the Board of Directors of TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **TITAN BIOTECH LIMITED** (the "Company") for the quarter ended **30th June, 2022** (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation") as amended, read with SEBI Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 (the "Circular").
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Sunita Agrawal & Co**
Chartered Accountants
ICAI FRN- 515225C


(CA Sunita Agrawal)
Partner
Membership No.095196
UDIN-22095196AOSTPM4688



Delhi, Aug. 10, 2022



Sunita Agrawal & Co.

(Chartered Accountants)

Limited Review Report on Unaudited Consolidated financial results of Titan Biotech Limited for the quarter ended 30th June 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **TITAN BIOTECH LIMITED** ("the Company") and its Associate, for the Quarter ended **30th June, 2022** which are included in the accompanying Statement of Consolidated Unaudited Financial Results together with relevant notes thereon ("the Statement"). The statement has been prepared by the Company pursuant of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended read with SEBI Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 ("the Circular").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Holding Company personnel and analytical procedures applied to group financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. The Statement includes results of the Holding Company- Titan Biotech Limited and Associate Company - Peptech Biosciences Limited.
5. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of its associate which have been approved and furnished to us by the management. Our conclusion on the Statement is not modified in respect of the above matter.
6. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The unaudited consolidated financial results also includes the Group's share of net profit/(loss) after tax of Rs. 350.47 Lacs and total comprehensive income of Rs.350.47 Lacs for the quarter ended 30th June, 2022 respectively, as considered in the consolidated unaudited financial results, in respect of one associate, based on their interim financial results which have not been reviewed/audited by their auditor. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.
Our conclusion on the Statement is not modified in respect of the above matter.

For Sunita Agrawal & Co
Chartered Accountants
ICAI FRN- 515225C


(CA Sunita Agrawal)
Partner
Membership No.095196
UDIN-22095196AOSUPJ3773
Delhi, Aug. 10, 2022



Head Office : 10, Giriraj Nagar, Inside Fort, Bharatpur (Rajasthan)-321001, Ph. : 05644-225679, M : 9899567391

Branch Office : A-160, Boulevard, Hotel Crowne Plaza, Mayapuri, Phase-1, Delhi-110091, Ph. : 011-49868379

E-mail : sunitaca_97@yahoo.com | sac.icai@gmail.com | info@taxfirst.in

Web : www.consultants.tax, www.taxfirst.in

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hr@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2022

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	STANDALONE			
		QUARTER ENDED		YEAR ENDED	
		30.06.2022	31.03.2022	30.06.2021	31.03.2022
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	INCOME				
	Revenue from operations	3,499.62	3,108.67	3,334.61	12,354.89
	Other Income	31.64	38.13	12.42	94.13
	Total Income	3,531.26	3,146.80	3,347.03	12,449.02
2	EXPENSES				
	Cost of Materials Consumed	1,784.39	1,446.56	1,491.55	5,912.24
	Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(60.73)	(36.41)	6.81	(17.30)
	Employee Benefit Expenses	379.95	421.30	313.60	1,433.00
	Finance Costs	17.59	17.81	23.98	78.39
	Depreciation and Amortization Expenses	60.45	69.20	55.04	236.91
	Other Expenses	589.37	586.77	419.75	1,908.88
	Total Expenses	2,771.02	2,505.23	2,310.73	9,552.12
3	Profit/(loss) before exceptional items and tax (1-2)	760.24	641.57	1,036.30	2,896.90
4	Exceptional Items	-	-	-	-
5	Profit/ (loss) before tax (3+4)	760.24	641.57	1,036.30	2,896.90
6	Tax expense:				
	(i) Current Tax	181.86	175.35	290.43	735.07
	(ii) Deferred Tax	0.65	(0.01)	1.89	(6.57)
	(iii) Earlier year taxes	-	(0.01)	-	(0.03)
	Total Tax (I+II)	182.51	161.28	292.32	728.47
7	Profit (Loss) for the period after Tax (5-6)	577.73	480.29	743.98	2,168.43
8	Other comprehensive income (Net of Tax)				
A	Items that will not be reclassified to profit or loss	-	(2.08)	-	(2.08)
	Re-measurement gain on defined benefit plans	-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	(2.08)	-	(2.08)
	Total Other Comprehensive Income for the period (A+B)(net of taxes)	-	(2.08)	-	(2.08)
9	Total Comprehensive Income for the period (7+8)	577.73	478.21	743.98	2,166.35
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37
11	Other Equity	-	-	-	7,798.04
12	Earnings per equity share (face value of Rs. 10/- each) not annualised				
	(1) Basic	6.99	5.81	9.00	26.24
	(2) Diluted	6.99	5.81	9.00	26.24

Notes:

- The above unaudited standalone financial results for the quarter ended on 30.06.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on August 10, 2022. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30th June 2022 and re-measured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 30.06.2022 includes sale of Products of Rs. 47.59 Lakhs the demand for which arose due to Covid 19 Pandemic.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of
for TITAN BIOTECH LIMITED



NARESH KUMAR SINGLA
Managing Director
DIN-00027448

Place : Delhi
Dated : 10.08.2022

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A BICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011-71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30/06/2022

(Rs. IN LAKHS) except for EPS

Sr. No.	PARTICULARS	STANDALONE			
		QUARTER ENDED		YEAR ENDED	
		30.06.2022	31.03.2022	30.06.2021	31.03.2022
	UNAUDITED	AUDITED	UNAUDITED	AUDITED	
1	Total Income from Operations (Net)	3,531.26	3,146.80	3,347.00	12,449.02
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	760.24	641.57	1,036.30	2,896.90
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	760.24	641.57	1,036.30	2,896.90
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	577.73	480.29	743.98	2,168.43
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	577.73	478.21	743.98	2,166.35
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	7,796.04
8	Number of Shares (of INR. 10/- each)				
	(a) Basic	6.99	5.81	9.00	26.24
	(b) Diluted	6.99	5.81	9.00	26.24

NOTES:-

- The above is an extract of the detailed format of standalone unaudited Financial Results for the quarter ended on 30.06.2022 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone unaudited Financial Results for the said quarter ended on 30.06.2022 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com. The statutory auditors of the company have carried out a limited review of the aforesaid results.
- The above unaudited standalone financial results for the quarter ended on 30.06.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on August 10, 2022. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30th June 2022 and measured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 30.06.2022 includes sale of Products of Rs. 47.59 Lakhs the demand for which arose due to Covid 19 Pandemic.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

Place : Delhi
Dated : 10.08.2022



For and on behalf of Board of
for TITAN BIOTECH LIMITED

(Signature)
NARESH KUMAR SINGLA
Managing Director
DIN-00027448

TITAN BIOTECH LIMITED
Standalone Balance Sheet as at 30th June, 2022

(Rs. in Lakhs.)

Particulars	As at	
	30/06/2022 Unaudited	31/03/2022 Audited
I ASSETS		
1. Non-Current Assets		
a. Property, Plant and Equipment	2,526.62	2,554.21
b. Capital Work-in-Progress	450.02	363.39
c. Right of use Assets	923.99	933.84
d. Intangible assets	10.04	10.46
e. Financial Assets		
(i) Investments	678.75	403.12
(ii) Other Financial Assets	169.66	168.54
Total Non-current assets	4,759.08	4,433.56
2. Current Assets		
a. Inventories	3,760.80	3,467.97
b. Financial Assets		
(i) Trade receivables	1,979.34	1,635.91
(ii) Cash and cash equivalents	272.34	681.39
c. Current Tax Assets (Net)	-	-
d. Other Current Assets	344.43	537.36
Total Current assets	6,356.91	6,322.63
TOTAL ASSETS	11,115.99	10,756.19
II. EQUITY AND LIABILITIES		
A Equity		
a. Equity Share Capital	826.37	826.37
b. Other Equity	8,375.77	7,798.04
TOTAL EQUITY	9,202.14	8,624.41
B Liabilities		
1. Non-Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	194.21	108.11
(ii) Lease liabilities	124.26	110.86
b. Deferred tax liabilities (Net)	128.19	127.55
c. Provisions	143.27	143.27
Total Non-Current Liabilities	589.93	489.79
2. Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	149.93	471.77
(ii) Lease liabilities	8.33	28.97
(iii) Trade payables	383.28	415.99
(iv) Other financial liabilities	287.03	490.53
b. Other current liabilities	396.64	174.83
c. Provisions	28.51	28.51
d. Current Tax Liabilities (Net)	70.20	31.39
Total Current Liabilities	1,323.92	1,641.99
TOTAL EQUITY AND LIABILITIES	11,115.99	10,756.19



For Titan Biotech Limited

(Signature)
[Naresh Kumar Singla]
Managing Director
DIN-00027448

Place : Delhi
Date : 10.08.2022

TITAN BIOTECH LIMITED
Standalone Cash Flow Statement for the period ended 30th June, 2022

(Rs. in Lakhs.)

Particulars	Period ended	Year ended
	30/06/2022 Unaudited	31/03/2022 Audited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before Tax	760.24	2,896.90
Adjustment for :		
Finance Costs	17.59	78.39
Provisions	-	27.87
Earlier year Taxes	-	0.03
Depreciation and Amortization Expenses	60.45	236.91
Operating profit before working capital changes	838.28	3,240.10
Changes in working Capital:		
Inventories	(292.80)	(785.15)
Trade and other Receivables	(151.63)	203.24
Trade and other Payables	(14.40)	248.83
Cash generation from Operation	379.45	2,907.02
Payment of Direct Taxes	(143.06)	(711.77)
Net Cash generated/ (used) - Operating Activities	236.39	2,195.25
B. CASH FLOW FROM INVESTMENT ACTIVITIES		
Purchase of Investment in shares	(275.63)	(275.63)
Purchase of Fixed Assets (incl.Capital WIP)	(119.08)	(631.12)
Right of use assets	9.85	(736.90)
Net Cash Generated/ (Used) - Investing Activities	(384.86)	(1,643.65)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of Long-term Borrowings	86.09	(74.58)
Repayment of Lease Liabilities	(7.24)	(25.02)
Proceeds/(Repayment) of Short-term Borrowings (Net)	(321.84)	(99.12)
Finance Cost paid	(17.59)	(78.39)
Dividend paid	-	(123.96)
Net Cash Generated/ (Used) - Financing Activities	(260.58)	(401.07)
Net Increase/ (Decrease) in Cash and Cash Equivalents	(409.05)	150.53
Add : Opening Cash and Cash Equivalents	681.39	530.86
Closing Cash and Cash Equivalents (refer note-8)	272.34	681.39

Notes:

1. The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7).
2. Figures in bracket represent outflows.
3. Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

For Titan Biotech Limited



(Signature)
 [Naresh Kumar Singla]
 Managing Director
 DIN-00027448

Place : Delhi
 Date : 10.08.2022

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019
 Phone No. 011-71229900, Email : hr@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013307

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2022
 (Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	CONSOLIDATED			
		QUARTER ENDED		YEAR ENDED	
		30.06.2022	31.03.2022	30.06.2021	31.03.2022
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	INCOME				
	Revenue from operations	3,499.62	3,293.59	4,143.97	15,280.97
	Other Income	31.64	39.41	14.35	102.25
	Total Income	3,531.26	3,333.00	4,158.32	15,383.22
2	EXPENSES				
	Cost of Materials Consumed	1,784.39	1,540.45	1,955.90	7,547.79
	Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(60.73)	(37.32)	(23.87)	(80.16)
	Employee Benefit Expenses	379.95	442.90	365.20	1,613.74
	Finance Costs	17.59	20.34	37.53	138.26
	Depreciation and Amortization Expenses	60.45	70.55	58.40	253.84
	Other Expenses	589.37	605.43	406.00	2,079.92
	Total Expenses	2,771.02	2,642.35	2,799.16	11,563.39
3	Profit/(loss) before exceptional items and tax (1-2)	760.24	690.65	1,359.16	3,819.83
4	Exceptional Items	-	-	-	-
5	Profit/(Loss) before tax (3+4)	760.24	690.65	1,359.16	3,819.83
6	Tax expense:				
	(i) Current Tax	181.80	189.66	371.77	970.33
	(ii) Earlier year taxes	-	-	-	1.60
	(iii) Deferred Tax	0.65	(13.97)	1.81	(7.50)
	Total Tax (1+i)	182.51	175.69	373.58	964.52
7	Profit (Loss) for the period after Tax (5-6)	577.73	514.96	985.58	2,855.31
8	Share in Profit of Associate	172.72	-	-	19.03
9	Profit (Loss) for the period (7+8)	750.45	514.96	985.58	2,874.34
10	Other comprehensive income (Net of Tax)				
A	Items that will not be reclassified to profit or loss				
	Re-measurement gain on defined benefit plans	-	(2.08)	-	(2.08)
B	(i) Items that will be reclassified to profit or loss				
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income for the period (A+BX/net of taxes)	-	(2.08)	-	(2.08)
11	Total Comprehensive Income for the period (7+8)	750.45	512.88	985.58	2,872.26
12	Net profit attributable to:				
	Owners of the holding company	-	498.70	872.32	2,513.30
	Non-controlling interest	-	16.25	113.26	322.01
13	Other comprehensive income attributable to:				
	Owners of the holding company	-	(1.71)	-	(1.71)
	Non-controlling interest	-	(0.37)	-	(0.37)
14	Total Comprehensive Income attributable to (10+11)				
	Owners of the holding company	-	496.99	872.32	2,531.59
	Non-controlling interest	-	15.88	113.26	321.64
15	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37
16	Other Equity	-	-	-	9,040.49
17	Earnings per equity share (face value of Rs 10/- each) not annualised				
	(1) Basic	0.08	6.03	10.56	30.66
	(2) Diluted	0.08	6.03	10.56	30.66

Notes:

- The above consolidated unaudited financial results for the quarter ended on 30.06.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on August 10, 2022. The statutory auditors of the company have carried out a limited review of the aforesaid results. The results for the quarter ended June 30, 2022, are available on the BSE Limited website (bseindia.com) and on the company's Website (titanbiotechltd.com)
- The consolidated unaudited financial results for the quarter ended on 30.06.2022 include the results of following:-
Associate Company - Peptech Biosciences Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30 June 2022 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 30.06.2022 includes sale of Products of Rs. 47.59 Lakhs the demand for which arose due to Covid 19 Pandemic.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.



For and on behalf of Board of
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448

Place : Delhi
Dated : 10.08.2022

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2022

(Rs. IN LAKHS) except for EPS

S.NO.	PARTICULARS	CONSOLIDATED			
		QUARTER ENDED		YEAR ENDED	
		30.06.2022	31.03.2022	30.06.2021	31.03.2022
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	3,531.26	3,333.00	4,158.32	15,383.22
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	760.24	690.65	1,359.16	3,819.83
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	760.24	690.65	1,359.16	3,819.83
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	750.45	514.96	985.58	2,874.34
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	750.45	512.88	985.58	2,872.26
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet				
8	Earning Per Share (of INR 10/- each)				
	(a) Basic	9.08	6.03	10.56	30.66
	(b) Diluted	9.08	6.03	10.56	30.66

NOTES :

- The above is an extract of the detailed format of consolidated unaudited Financial Results for the quarter ended on 30.06.2022 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated unaudited Financial Results for the said quarter ended on 30th June 2022 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com
- The above consolidated unaudited financial results for the quarter ended on 30.06.2022 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on August 10, 2022. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30.06.2022 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The total sale for the quarter ended 30.06.2022 includes sale of Products of Rs. 47.59 Lakhs the demand for which arose due to Covid 19 Pandemic.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

Place : Delhi
Dated : 10.08.2022



For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

(Signature)
NARESH KUMAR SINGLA
Managing Director
DIN-00027448

TITAN BIOTECH LIMITED
Consolidated Balance Sheet as at 30th June, 2022

(Rs. in Lakhs.)

Particulars	As at	
	30/06/2022 Unaudited	31/03/2022 Audited
I. ASSETS		
1. Non-Current Assets		
a. Property, Plant and Equipment	2,526.62	2,695.68
b. Capital Work-in-Progress	450.02	796.63
c. Right of use Assets	923.99	1,509.60
d. Intangible assets	10.04	10.45
e. Other Non Current Assets	-	11.40
f. Financial Assets	851.47	
(i) Investments	169.66	181.40
(ii) Other Financial Assets		
Total Non-current assets	4,931.80	5,205.16
2. Current Assets		
a. Inventories	3,760.80	4,229.46
b. Financial Assets	1,979.34	2,167.08
(i) Trade receivables	272.34	1,560.67
(ii) Cash and cash equivalents	-	-
c. Current Tax Assets (Net)	344.43	1,177.51
d. Other Current Assets		
Total Current assets	6,356.91	9,134.72
TOTAL ASSETS	11,288.71	14,339.88
II. EQUITY AND LIABILITIES		
A Equity		
a. Equity Share Capital	826.37	826.37
b. Other Equity	8,548.49	9,040.49
c. Non Controlling Interest	-	674.39
TOTAL EQUITY	9,374.86	10,541.25
B Liabilities		
1. Non-Current Liabilities		
a. Financial Liabilities	194.21	839.84
(i) Borrowings	124.26	154.72
(ii) Lease liabilities	128.19	130.73
b. Deferred tax liabilities (Net)	143.27	150.50
c. Provisions		
Total Non-Current Liabilities	589.93	1,275.79
2. Current Liabilities		
a. Financial Liabilities	149.93	747.00
(i) Borrowings	8.33	33.37
(ii) Lease liabilities	383.28	754.79
(iii) Trade payables	287.03	615.75
(iv) Other Financial Liabilities	396.64	217.41
b. Other current liabilities	28.51	28.87
c. Provisions	70.20	125.65
d. Current Tax Liabilities (Net)		
Total Current Liabilities	1,323.92	2,522.84
TOTAL EQUITY AND LIABILITIES	11,288.71	14,339.88

Place : Delhi
Date : 10.08.2022



For Titan Biotech Limited

Naresh Kumar Singla
[Naresh Kumar Singla]
Managing Director
DIN-00027448

TITAN BIOTECH LIMITED
Consolidated Cash Flow Statement for the period ended 30th June, 2022

(Rs. in Lakhs.)

Particulars	Period ended	Year ended
	30/06/2022	31/03/2022
	Unaudited	Audited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before Tax	760.24	3,819.83
Adjustment for :		
Finance Costs	17.59	128.26
Earlier year Taxes	-	(1.69)
Provision for employees Benefits	-	27.87
Depreciation and Amortization Expenses	60.45	253.84
	838.28	4,228.11
Operating profit before working capital changes		
Changes in working Capital:		
Inventories	(292.80)	(975.67)
Trade and other Receivables	(151.63)	(652.37)
Trade and other Payables	(14.40)	566.24
Cash generation from Operation	379.45	3,166.31
Payment of Direct Taxes	(143.06)	(880.39)
Net Cash generated/ (used) - Operating Activities	236.39	2,285.92
B. CASH FLOW FROM INVESTMENT ACTIVITIES		
Purchase of Fixed Assets (incl.Capital WIP and Right of use assets)	(119.08)	(1,099.49)
Right of use assets	9.85	(779.01)
Purchase of Investments	(275.63)	-
Net Cash Generated/ (Used) - Investing Activities	(384.86)	(1,878.50)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of Long-term Borrowings	86.09	272.79
Repayment of Lease Liabilities	(7.24)	23.25
Proceeds/(Rapyment)of Short-term Borrowings(Net)	(321.84)	-
Share application pending for allotment	-	564.37
Finance Cost paid	(17.59)	(128.26)
Dividend paid	-	(123.96)
Net Cash Generated/ (Used) - Financing Activities	(260.58)	608.19
Net Increase/ (Decrease) in Cash and Cash Equivalents	(409.05)	1,015.61
Add : Opening Cash and Cash Equivalents	681.39	545.06
Closing Cash and Cash Equivalents	272.34	1,560.67

Notes:

- The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7).
- Figures in bracket represent outflows.
- Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

Place : Delhi
 Date : 10.08.2022



For Titan Biotech Limited

(Signature)
 [Naresh Kumar Singla]
 Managing Director
 DIN-00027448